Novo Nordisk Announces Insider Trading Activities
This announcement provides details about transactions involving Novo Nordisk shares conducted by the company's board members, executives, and their associated individuals, in accordance with Article 19 of Regulation No. 596/2014 concerning market abuse.
The board members, executives, and their associated persons have reported these transactions to Novo Nordisk, granting the company power of attorney to publish the trading activities on their behalf.
Board Members and Executives Involved
Below is a summary of the trading activities in shares issued by Novo Nordisk.
Transaction Information
Details of the individual responsible for managerial duties/person closely associated: Sylvie Louise Grégoire, Member of the Board of Directors. This is the initial notification.
Details of the issuer: Novo Nordisk A/S, LEI: 549300DAQ1CVT6CXN342.
Transaction details: Financial instrument description: ADRs (Identification code: NVO). Nature of the transaction: Purchase of ADRs.
Aggregated Transaction Information
Aggregated volume: 1,500 ADRs. Total price: DKK 1,368,944.39.
Transaction date: 2024-08-19. Transaction location: New York Stock Exchange.
About Novo Nordisk
Novo Nordisk is a prominent global healthcare company, established in 1923 and based in Denmark. Its mission is to drive progress in combating serious chronic diseases, with a strong foundation in diabetes care. The company is known for its scientific innovations, expanding access to medications, and striving to prevent and ultimately cure diseases. Novo Nordisk employs approximately 69,000 people across 80 countries and markets its products in around 170 countries. The company's B shares are traded on Nasdaq Copenhagen (Novo-B), and its ADRs are listed on the New York Stock Exchange (NVO).
Contact Information
Media Contacts:
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
Investor Contacts:
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com
Frequently Asked Questions
What transactions are disclosed in this announcement?
This announcement reveals transactions involving Novo Nordisk shares carried out by board members and executives.
Who is the person mentioned in the announcement?
Sylvie Louise Grégoire is named as a member of the Board of Directors.
What is the purpose of this disclosure?
This disclosure complies with Article 19 of Regulation No. 596/2014 regarding market abuse.
What type of shares were involved in the transactions?
The transactions involved American Depositary Receipts (ADRs).
How can I contact Novo Nordisk for more information?
You can contact the media or investor relations representatives listed in the announcement for further information.